<DOC>
	<DOCNO>NCT02149017</DOCNO>
	<brief_summary>To evaluate pharmacokinetics , safety efficacy SNUBH-NM-333 ( 18F ) , new diagnostic radiopharmaceutical PET image amyloid plaque , Alzheimer 's disease patient healthy volunteer .</brief_summary>
	<brief_title>Phase 1 Phase 2 Clinical Trials SNUBH-NM-333 ( 18F )</brief_title>
	<detailed_description>The investigator perform whole-body brain kinetic modeling SNUBH-NM-333 ( 18F ) optimize image acquisition procedure . Five young healthy subject participate Whole-body positron emission tomography /computed tomographic ( PET/CT ) scan midfemoral position head approximately 5-10 mCi SNUBH-NM-333 ( 18F ) injection . For brain PET/CT amyloid imaging , another five young healthy subject scan dynamically windows 0-180 min injection SNUBH-NM-333 ( 18F ) , arterial sampling . The investigator compare different analysis method compartmental model standardized uptake value ratio determine optimal acquisition window . And 10 AD patient 10 elderly healthy control also participate brain amyloid image compare SNUBH-NM-333 ( 18F ) brain retention AD patient versus healthy elderly .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy young control 20 30 year old subjective memrory complaint Cognitively normal elderly Clinical Dementia Rating score 0 Alzheimer 's disease ( AD ) patient meet DSMIV criterion dementia NINCDSADRDA criterion probable AD present serious medical , psychiatric , neurological disorder could affect mental function ; evidence focal brain lesion MRI ; presence severe behavioral communication problem</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>amyloid plaque</keyword>
	<keyword>Positron-Emission Tomography</keyword>
	<keyword>radiopharmaceutical</keyword>
</DOC>